Testing utidelone with capecitabine for HER2-negative breast cancer that has spread to the brain
Original title: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid-stage study, so the drugs are still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing two cancer drugs in people whose breast cancer has spread to the brain.
Who this trial is for. This trial is for people with HER2-negative breast cancer that has spread to the brain. It tests the drug utidelone on its own and together with capecitabine.
Where it stands. The trial has not reported results. It is measuring how well the drugs work in the brain and in the rest of the body. It is also checking how safe they are. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Some people may want to learn more about this study. If it sounds like your situation, you can ask your care team about it. They can tell you if it makes sense for you.
What it doesn't mean: It does not mean these drugs are proven. A trial is a test, not care your own doctor can give you. Being in a trial does not mean it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.